

Product Name: GDC-0994 Revision Date: 01/10/2021

Product Data Sheet

GDC-0994

Cat. No.: B5817

1453848-26-4 CAS No.:

Formula: C21H18CIFN6O2


M.Wt: 440.86

Synonyms:

Target: MAPK Signaling

Pathway: MEK1/2

Storage: Store at -20°C



In BRAFV600E cell lines, treatment with GDC-0994 resulted in stronger

Solvent & Solubility

≥44.1 mg/mL in DMSO; insoluble in H2O; ≥19.2 mg/mL in EtOH

In Vitro

Preparing Stock Solutions	Solvent Concentration	1mg	5mg	10mg
	1 mM	2.2683 mL	11.3415 mL	22.6829 mL
	5 mM	0.4537 mL	2.2683 mL	4.5366 mL
	10 mM	0.2268 mL	1.1341 mL	2.2683 mL

Please refer to the solubility information to select the appropriate solvent.

Biological Activity

Applications:

Shortsummary	ERK1/2 inhibitor	
IC ₅₀ & Target		
	Cell Viability Assay	
	Cell Line:	BRAFV600E cell lines
	Preparation method:	The solubility of this compound in DMSO is >22.1mg/mL. General tips for
In Vitro		obtaining a higher concentration: Please warm the tube at 37 °C for 10 minutes
		and/or shake it in the ultrasonic bath for a while. Stock solution can be stored
		below -20°C for several months.

		pathway inhibition and subsequent suppression of cell proliferation when compared to BRAF inhibitors.			
	Animal experiment				
In Vivo	Animal models:	Mice bearing KRAS-mutant and BRAF-mutant human xenograft tumors, HT29 colorectal cancer xenograft model.			
	Dosage form:	Oral administration, daily			
	Applications:	Daily, oral administration of GDC-0994 resulted in significant single-agent activity in KRAS-mutant and BRAF-mutant human xenograft tumors in mice.			
	Other notes:	Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal.			

Product Citations

- 1. White SM, Avantaggiati ML, et al. "YAP/TAZ Inhibition Induces Metabolic and Signaling Rewiring Resulting in Targetable Vulnerabilities in NF2-Deficient Tumor Cells." Dev Cell. 2019 May 6;49(3):425-443.e9.PMID:31063758
- 2. Zhang XH, Li CY, et al. "Pro-angiogenic activity of isoliquiritin on HUVECs in vitro and zebrafish in vivo through Raf/MEK signaling pathway." Life Sci. 2019 Apr 15;223:128-136.PMID:30876941
- 3. Duan T, Cil O, et al. "Intestinal epithelial potassium channels and CFTR chloride channels activated in ErbB tyrosine kinase inhibitor diarrhea." JCI Insight. 2019 Feb 21;4(4). pii: 126444.PMID:30668547

See more customer validations on www.apexbt.com.

References

- [1]. Nambu T, Iwai K, Shibata S, et al. Identification of driver of anti-tumor activity of TAK-931 in human colorectal cancer xenograft model[J]. European Journal of Cancer, 2016, 69: S30.
- [2]. Robarge K, Schwarz J, Blake J, et al. Abstract DDT02-03: Discovery of GDC-0994, a potent and selective ERK1/2 inhibitor in early clinical development. AACR Annual Meeting, 2014, San Diego, CA.

Caution

FOR RESEARCH PURPOSES ONLY.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

Specific storage and handling information for each product is indicated on the product datasheet. Most APExBIO products are stable under the recommended conditions. Products are sometimes shipped at a temperature that differs from the recommended storage temperature. Shortterm storage of many products are stable in the short-term at temperatures that differ from that required for long-term storage. We ensure that the product is shipped under conditions that will maintain the quality of the reagents. Upon receipt of the product, follow the storage recommendations on the product data sheet.

APExBIO Technology

www.apexbt.com

7505 Fannin street, Suite 410, Houston, TX 77054.
Tel: +1-832-696-8203 | Fax: +1-832-641-3177 | Email: info@apexbt.com



APE, BIO

APE, BIO

APE BIO

APE BIO

APE, BIO

APE BIO